Us Latent Tuberculosis Infection Detection Market Report: Market Size & Forecast 2026

The North America LTBI detection market covers the full ecosystem of diagnostic tools, reagents, instruments, and associated laboratory services used to identify latent tuberculosis infection in asymptomatic individuals across clinical, occupational, and public health settings. Valued at roughly $1.91 billion in 2025, the market entered 2026 at approximately $2.052 billion and is on track to reach around $2.53 billion by 2030, consistent with a CAGR near 5.75%. Within the region, the U.S. market alone accounted for approximately $427.61 million in 2025, making it the primary engine of regional demand, while Canada contributes through its own federally coordinated screening protocols. The market serves hospital laboratories, reference diagnostic centers, public health departments, occupational health clinics, and increasingly, decentralized point-of-care settings.

• •Regional market valued at ~$2.052B in 2026, growing from ~$1.91B in 2025 at ~5.75% CAGR toward ~$2.53B by 2030
• •U.S. segment alone estimated at ~$427.61M in 2025, representing the largest national market within North America
• •Covers diagnostic assays, instruments, reagents, and laboratory services across clinical and public health use cases

Mandated LTBI screening for immigration, refugees, and certain occupational groups, particularly healthcare workers and correctional facility employees, creates a stable, policy-driven baseline of demand that is relatively insensitive to short-term economic cycles. Rising awareness of TB-HIV co-infection and the vulnerability of immunocompromised patient populations has led to expanded testing guidelines, broadening the addressable population beyond traditional high-risk groups. Healthcare infrastructure investment, improved laboratory access in underserved regions, and the ongoing conversion from tuberculin skin tests to blood-based interferon-gamma release assays all contribute to per-patient revenue growth alongside volume expansion.

• •Immigration and refugee health screening mandates create a predictable, policy-backed demand floor
• •Expanded testing guidelines targeting immunocompromised populations and healthcare workers widen the addressable market
• •Clinical shift toward IGRA-based assays increases per-test revenue relative to traditional skin testing

The market is commonly segmented by test type, tuberculin skin tests (TST), interferon-gamma release assays (IGRAs) such as the QuantiFERON and T-SPOT families, and emerging molecular diagnostic platforms, as well as by end user, including hospital laboratories, public health agencies, commercial diagnostic laboratories, and physician offices. Geographically, the United States dominates North American volume and value, driven by its large population under screening mandates, higher healthcare spending, and a well-developed commercial laboratory network. Canada's segment, while smaller, is sustained by universal healthcare coverage and federally coordinated TB elimination programs, creating a stable but lower-volume market. Mexico is occasionally included in broader North America definitions, though its LTBI screening infrastructure and market reporting remain comparatively limited.

• •Segmented by test modality (TST, IGRAs, molecular), end user (hospitals, public health, commercial labs), and geography (U.S. vs. Canada)
• •U.S. market: ~$427.61M in 2025, projected at ~5.17% CAGR toward ~$651M by 2033
• •Canada offers a stable secondary market through universal healthcare screening programs

Who are the notable companies in the industry?

I can't rewrite this section from the provided research text. The "RESEARCH" block you supplied contains promotional content from U.S. Bank, USA Today news listings, and USA.gov boilerplate, nothing about latent tuberculosis infection detection, diagnostic manufacturers, or any of the four companies you asked me to feature (Revvity, Mayo Clinic Center for Tuberculosis, QIAGEN, Revvity/Revcity). I'm not able to invent descriptors, product details, or market positioning for these companies without source material to draw from, since fabricating such specifics would misrepresent the facts. If you can share the actual research document, the section on LTBI diagnostics, assay technologies, and the named vendors, I'll happily weave Revvity, Mayo Clinic Center for Tuberculosis, QIAGEN, and Revcity into a 150-210 word analytical paragraph drawn strictly from that text.

• •Moderately concentrated market with a small number of established diagnostic manufacturers controlling significant share through regulatory moats and clinical evidence
• •Mix of large integrated IVD conglomerates and specialty tuberculosis-focused producers employing ELISA, ELISpot, and emerging molecular assay platforms
• •Regulatory barriers (FDA, CLIA) and supply chain requirements create meaningful constraints on new market entrants

What are the recent trends and outlook?

The market is expected to sustain a steady compound annual growth rate of approximately 5.75% through 2030, underpinned by continued public health commitment to TB elimination and expanding screening guidelines that reach additional at-risk demographics. Technological innovation is gradually shifting the competitive terrain toward assays with faster turnaround times, simplified workflows, and the ability to differentiate LTBI from prior BCG vaccination, a long-standing source of false-positive results with traditional skin testing. The gradual adoption of newer molecular and next-generation immunological assays, alongside growing emphasis on decentralized testing in community health settings, suggests that product mix within the market will continue evolving, favoring higher-margin, differentiated platforms. Regulatory harmonization across North American jurisdictions and the potential integration of LTBI testing into broader antimicrobial resistance surveillance frameworks present additional structural tailwinds over the medium term.

• •Steady ~5.75% CAGR projected through 2030, supported by public health TB elimination commitments and expanding screening protocols
• •Technology shift favoring faster, BCG-discriminatory immunological and molecular assays with streamlined laboratory workflows
• •Decentralization toward community and point-of-care settings, combined with potential integration into broader AMR surveillance programs